vimarsana.com

Page 98 - டிஸ்னிலேண்ட் உல்லாசப்போக்கிடம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Disneyland Announces When It Will Reopen to Non-California Residents | 96 1 The Beat

Tino Cochino Radio is the fastest growing radio show in the country currently airing in 65+ cities. The cast includes Tino Cochino, Serina Perez, Nicasio and Executive Producer, Matt. From Tino’s tattoo addiction and Serina becoming a new mom, to Matt trying to manage three kids and Nicasio not thinking before he speaks, we’re sharing it all.

Disneyland Announces When It Will Reopen to Non-California Residents | REAL 92 3

By @tinocochinoradio, @theeserinaperez California Adventure at Sunset. Disneyland has announced the happiest place on earth will finally reopen to non-California residents beginning June 15th, including Disney California Adventure Park. Disneyland Resort theme parks to welcome back guest from outside California June 15, the tweet said. Disney s new attraction The Avengers Campus also opens June 4, so out-of-town visitors will be able to check it out.

Coronavirus update: Another new treatment drug, investigating the virus origin

Coronavirus update: Another new treatment drug, investigating the virus’ origin Fewer people are filing unemployment claims 05/27/2021 Total U.S. confirmed cases: 33,192,974 (33,171,024) Total U.S. deaths: 592,432 (591,116) Total global cases: 168,520,476 (167,961,302) Total global deaths: 3,500,945 (3,488,454) FDA gives emergency approval to new treatment drug The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to a new coronavirus treatment drug made by GlaxoSmithKline and Vir Biotechnology. The monoclonal antibody drug has been shown to be effective in treating early COVID-19 infections. The drug, called sotrovimab, is the third antibody product that the FDA has authorized to treat patients in the early stages of the disease but who may be vulnerable to a severe case.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.